{"id":"autologous-conditioned-serum","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Pain"},{"rate":"5-10%","effect":"Swelling"},{"rate":"1-5%","effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL2109149","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The serum is collected from the patient's own blood, which is then used to stimulate the body's natural healing processes. This can help to reduce inflammation and promote tissue repair.","oneSentence":"Autologous Conditioned Serum is a treatment that uses a patient's own blood to stimulate healing and reduce inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:29:45.820Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoarthritis"},{"name":"Rheumatoid Arthritis"}]},"trialDetails":[{"nctId":"NCT06959771","phase":"PHASE1, PHASE2","title":"Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-16","conditions":"CD40L-HyperIgM Syndrome","enrollment":1},{"nctId":"NCT07473232","phase":"NA","title":"Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS)","status":"NOT_YET_RECRUITING","sponsor":"Pamukkale University","startDate":"2026-04-01","conditions":"Knee Arthritis Osteoarthritis, Platelet Rich Plasma Injection, Conditioned Serum","enrollment":60},{"nctId":"NCT06839326","phase":"NA","title":"Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder","status":"COMPLETED","sponsor":"Batman University","startDate":"2024-11-01","conditions":"Temporomandibular Joint Osteoarthritis","enrollment":75},{"nctId":"NCT05357482","phase":"PHASE1, PHASE2","title":"Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-05-12","conditions":"Sickle Cell Anemia, Beta Thalassemia","enrollment":40},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT06364423","phase":"PHASE1, PHASE2","title":"Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-03","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia","enrollment":132},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT04196413","phase":"PHASE1","title":"GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2020-06-04","conditions":"Glioma of Spinal Cord, Glioma of Brainstem","enrollment":97},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT00692939","phase":"PHASE1, PHASE2","title":"Autologous Stem Cell Transplantation for Crohn's Disease","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2012-06-26","conditions":"Crohn's Disease","enrollment":20},{"nctId":"NCT03352765","phase":"PHASE1","title":"A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-11-20","conditions":"Lymphoma","enrollment":28},{"nctId":"NCT04871607","phase":"PHASE2","title":"Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-02","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":33},{"nctId":"NCT05631899","phase":"PHASE1","title":"CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-04-03","conditions":"Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V","enrollment":9},{"nctId":"NCT03630211","phase":"PHASE2","title":"Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-07-31","conditions":"Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease","enrollment":8},{"nctId":"NCT04007029","phase":"PHASE1","title":"Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-10-04","conditions":"CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia","enrollment":24},{"nctId":"NCT02775292","phase":"PHASE1","title":"Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2017-01-03","conditions":"Adult Solid Neoplasm, Childhood Solid Neoplasm, Metastatic Neoplasm","enrollment":1},{"nctId":"NCT02722668","phase":"PHASE2","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-05-15","conditions":"Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma","enrollment":15},{"nctId":"NCT01318317","phase":"PHASE1, PHASE2","title":"Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2011-09-19","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":8},{"nctId":"NCT01413100","phase":"PHASE2","title":"Scleroderma Treatment With Autologous Transplant (STAT) Study","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-09-15","conditions":"Systemic Scleroderma","enrollment":21},{"nctId":"NCT05221645","phase":"PHASE2","title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southampton","startDate":"2022-06-27","conditions":"Diffuse Large B Cell Lymphoma","enrollment":65},{"nctId":"NCT03217643","phase":"PHASE2","title":"CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.","status":"COMPLETED","sponsor":"Imagine Institute","startDate":"2018-02-07","conditions":"Enteropathy Associated T-cell Lymphoma","enrollment":14},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT04002401","phase":"PHASE2","title":"Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2019-11-05","conditions":"Refractory Large B-cell Lymphoma","enrollment":27},{"nctId":"NCT05029206","phase":"","title":"Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-05-05","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":174},{"nctId":"NCT05482542","phase":"NA","title":"Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis","status":"WITHDRAWN","sponsor":"Scripps Health","startDate":"2023-01-01","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":""},{"nctId":"NCT01035463","phase":"PHASE1, PHASE2","title":"Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2009-11-12","conditions":"Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma","enrollment":74},{"nctId":"NCT05631886","phase":"PHASE1","title":"Combination of CAR-DC Vaccine and ICIs in Malignant Tumors","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-07-04","conditions":"Solid Tumor, Adult, Lymphoma, EphA2 Overexpression","enrollment":10},{"nctId":"NCT02366728","phase":"PHASE2","title":"DC Migration Study for Newly-Diagnosed GBM","status":"COMPLETED","sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","startDate":"2015-10-12","conditions":"Glioblastoma, Astrocytoma, Grade IV, Giant Cell Glioblastoma","enrollment":64},{"nctId":"NCT00096460","phase":"PHASE2, PHASE3","title":"Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2004-08","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":30},{"nctId":"NCT05398224","phase":"PHASE2","title":"R-MTX-zanbrutinib in Secondary CNS Lymphoma","status":"UNKNOWN","sponsor":"Peking University","startDate":"2021-02-26","conditions":"Secondary Central Nervous System Lymphoma","enrollment":45},{"nctId":"NCT04971005","phase":"PHASE2","title":"Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2021-08-27","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":1},{"nctId":"NCT02282514","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation for Stiff Person Syndrome (SPS)","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2014-10","conditions":"Stiff-Person Syndrome","enrollment":23},{"nctId":"NCT03342638","phase":"PHASE3","title":"Maximizing Outcome of Multiple Sclerosis Transplantation","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2017-11-08","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":66},{"nctId":"NCT00076752","phase":"PHASE2","title":"Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-01-30","conditions":"Lupus Erythematosus, Systemic","enrollment":9},{"nctId":"NCT00305682","phase":"PHASE2","title":"Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-06","conditions":"Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":295},{"nctId":"NCT03593902","phase":"PHASE2, PHASE3","title":"Cardiac Safe Transplants for Systemic Sclerosis","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2018-05-17","conditions":"Systemic Sclerosis, Scleroderma","enrollment":9},{"nctId":"NCT00303719","phase":"PHASE2","title":"Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-03-26","conditions":"Kidney Cancer, Leukemia, Lymphoma","enrollment":342},{"nctId":"NCT00992446","phase":"PHASE2","title":"Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2010-09-02","conditions":"Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":27},{"nctId":"NCT03829566","phase":"PHASE2, PHASE3","title":"Autologous Transplant To End NMO Spectrum Disorder","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2019-11","conditions":"Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder","enrollment":""},{"nctId":"NCT04154735","phase":"PHASE2","title":"Autologous Transplant Targeted Against Crohn's","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2019-11","conditions":"Crohn's Disease","enrollment":""},{"nctId":"NCT00568633","phase":"PHASE3","title":"Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-08","conditions":"Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)","enrollment":58},{"nctId":"NCT00392691","phase":"PHASE1","title":"Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2006-10","conditions":"Lymphoma","enrollment":20},{"nctId":"NCT03850080","phase":"PHASE2, PHASE3","title":"Autologous Conditioned Serum: Functional and Clinical Results","status":"COMPLETED","sponsor":"Ospedale San Raffaele","startDate":"2017-10-06","conditions":"Knee Osteoarthritis, Osteoarthritis, Knee, Cartilage Degeneration","enrollment":15},{"nctId":"NCT00278564","phase":"PHASE1","title":"Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2005-09","conditions":"MYOPATHY","enrollment":7},{"nctId":"NCT00278512","phase":"PHASE1","title":"Hematopoietic Stem Cell Support in Vasculitis","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2003-08","conditions":"Vasculitis","enrollment":7},{"nctId":"NCT00482053","phase":"PHASE2","title":"Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT","status":"TERMINATED","sponsor":"Stanford University","startDate":"2006-10","conditions":"Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":3},{"nctId":"NCT02858258","phase":"PHASE3","title":"ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Prof. Dr. M. Dreyling (co-chairman)","startDate":"2016-07","conditions":"Mantle Cell Lymphoma","enrollment":870},{"nctId":"NCT00899847","phase":"PHASE2","title":"Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-05","conditions":"Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma","enrollment":9},{"nctId":"NCT02619812","phase":"PHASE2","title":"Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2016-04","conditions":"Multiple Myeloma","enrollment":4},{"nctId":"NCT00644371","phase":"PHASE2","title":"Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2007-11","conditions":"Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT01118013","phase":"PHASE2","title":"Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-12","conditions":"Leukemia, Lymphoma, Lymphoproliferative Disorder","enrollment":6},{"nctId":"NCT01181271","phase":"PHASE2","title":"Tandem Auto-Allo Transplant for Lymphoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-08","conditions":"Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma","enrollment":42},{"nctId":"NCT01045889","phase":"PHASE2","title":"High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2007-01","conditions":"HIV-related Lymphoma, HIV Infections","enrollment":27},{"nctId":"NCT00646750","phase":"PHASE2","title":"Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2008-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":31},{"nctId":"NCT02529839","phase":"NA","title":"Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2015-10","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT01130194","phase":"PHASE2","title":"Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma","status":"COMPLETED","sponsor":"St. Louis University","startDate":"2006-07","conditions":"Follicular Lymphoma","enrollment":29},{"nctId":"NCT01679041","phase":"PHASE2","title":"High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment","status":"TERMINATED","sponsor":"Seah Lim M.D.","startDate":"2012-11","conditions":"Multiple Sclerosis","enrollment":1},{"nctId":"NCT00230035","phase":"PHASE2","title":"Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-09","conditions":"Systemic Lupus Erythematosus","enrollment":""},{"nctId":"NCT01679860","phase":"PHASE2","title":"Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2006-11","conditions":"Lymphoma, T-Cell, Peripheral","enrollment":92},{"nctId":"NCT01037738","phase":"PHASE1","title":"Study of Autologous Conditioned Serum After Anterior Cruciate Ligament Reconstructive Surgery","status":"COMPLETED","sponsor":"University of Zagreb","startDate":"2006-05","conditions":"Joint Instability","enrollment":62},{"nctId":"NCT00946374","phase":"PHASE2","title":"Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma","status":"UNKNOWN","sponsor":"Heidelberg University","startDate":"2004-07","conditions":"Mantle-Cell Lymphoma","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":173,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ACS","Orthokine®"],"phase":"phase_2","status":"active","brandName":"Autologous Conditioned Serum","genericName":"Autologous Conditioned Serum","companyName":"Ospedale San Raffaele","companyId":"ospedale-san-raffaele","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Autologous Conditioned Serum is a treatment that uses a patient's own blood to stimulate healing and reduce inflammation. Used for Osteoarthritis, Rheumatoid Arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}